Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells
Journal of Cellular and Molecular Medicine · 2023
DOI: 10.1111/jcmm.17935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2023. Verfasst von Aleksandra Simiczyjew und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Pathology, Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland. Hauptthemen laut MEDLINE: ErbB Receptors, Melanoma, Proto-Oncogene Proteins c-met, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Poland, Narodowe Centrum Nauki.
Abstract (Originalsprache)
Mucosal melanoma (MM) is a very rare and aggressive type of cancer for which immunotherapy or targeted therapy such as BRAF/MEK inhibitors, used in cutaneous melanoma, usually fail. Due to our earlier experience showing the high effectiveness of epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) inhibitors in reducing the activation of the MAPK and PI3K/AKT signalling pathways, we aim to test whether these drugs would also be effective for mucosal melanoma. Cells representing two commercially available mucosal melanoma cell lines (GAK and HMVII) and one cell line obtained from a patient's vaginal melanoma were treated with MET or EGFR inhibitors, or combinations of these agents. The dual‐inhibitor treatment strategy resulted in a decrease of cell proliferation, migration and invasion. Moreover, combinations of inhibitors led to reduction of pEGFR/EGFR and pMET/MET ratio and downregulation of PI3K/AKT and MEK/ERK1/2‐based signalling pathways. Our findings indicate a potential therapeutic strategy based on EGFR and MET inhibitors in mucosal melanoma, which should be further evaluated in vivo and in clinical experiments. They also suggest that targeting multiple receptor tyrosine kinases may block signalling crosstalk and possibly delay the appearance of resistance to kinase inhibitors in mucosal melanoma cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Pathology, Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland.
- Department of Oncology and Division of Surgical Oncology, Wroclaw Medical University, Wroclaw, Poland.
- Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw, Poland.
- Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Clinical and Experimental Pathology, Wroclaw Medical University, Wroclaw, Poland.
- Department of Pathology and Clinical Cytology, Jan Mikulicz-Radecki University Hospital, Wroclaw, Poland.
ORCID-Profile: Aleksandra Simiczyjew, Dorota Nowak
Förderung
- National Science Centre, Poland
- Narodowe Centrum Nauki
Zitieren
APA
Simiczyjew, A., Wądzyńska, J., Kot, M., Ziętek, M., Matkowski, R., Hoang, M. P., Donizy, P., & Nowak, D. (2023). Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17935
Vancouver
Simiczyjew A, Wądzyńska J, Kot M, Ziętek M, Matkowski R, Hoang MP, et al. Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells. Journal of Cellular and Molecular Medicine. 2023. doi:10.1111/jcmm.17935
BibTeX
@article{Simiczyjew2023,
author = {Simiczyjew, Aleksandra and Wądzyńska, Justyna and Kot, Magdalena and Ziętek, Marcin and Matkowski, Rafał and Hoang, Mai P and Donizy, Piotr and Nowak, Dorota},
title = {Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
doi = {10.1111/jcmm.17935}
}
EUVIMED